Previous 10 | Next 10 |
2023-07-13 17:03:37 ET MEI Pharma Inc. ( NASDAQ: MEIP ) postponed a special meeting for holders to vote on its merger with Infinity Pharmaceuticals ( NASDAQ: INFI ). The holder vote was postponed to July 23 from a scheduled vote on Friday, according to a statement. ...
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has postponed its special meeting in connection with the proposed transaction with Infinity Pharmaceuticals, Inc. (“Infinity”) to July 23, 2023, at 10:00 a.m. Eastern Time, unless postponed or adjo...
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. MEI is...
Glass Lewis Joins ISS in Recommending that MEI Shareholders Vote FOR the Infinity Transaction MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI)...
2023-07-05 15:27:46 ET Proxy advisory firm Institutional Shareholder Services has recommended that MEI Pharma ( NASDAQ: MEIP ) and Infinity Pharmaceuticals ( NASDAQ: INFI ) shareholders vote in favor of a planned merger between the two companies. MEI and Infinity shareho...
Affirms Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs MEI Pharma, Inc. (NASDAQ: MEIP) (the “...
Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs Combined Company Well-Positioned to Make a Difference in Cancer Care With Significant Potential to Deliver Improved Therapeutic Options for P...
2023-06-28 10:15:00 ET Summary GreenWood Investors is a bottom-up, mostly long, concentrated and constructivist global investment firm focused on areas of pessimism, structural inefficiencies and low competition. Overall performance of 1.3% in the fourth quarter trailed the market...
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the disclosure made today by Anson Advisors Inc. and Cable Car Capital LLC: Anson and Cable Car reiterated their formerly disclosed, unsolicited and non-binding proposal that our ...
Emphasizes the Board’s Failure to Adequately Consider the Superior Acquisition Proposal Presented by Anson Funds and Cable Car Capital Believes the Misguided Transaction with Infinity Pharmaceuticals Will Continue to Destroy Stockholder Value Have Voted Against the Propos...
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...